Summary of Consolidated Financial Results [ IFRS ]

for the First Three Months of the Fiscal Year Ending March 31, 2025
August 6, 2024

Listed company name : Sysmex Corporation

Code : 6869
Listed stock exchanges : Tokyo Stock Exchange
URL : www.sysmex.co.jp/en
Company representative : Kaoru Asano, President
Contact : Takuro Minami, Executive Vice President of
Corporate Business Administration
Phone : 078(265)-0500
Scheduled date for dividend payment : ―
Preparation of supplementary material for : Yes
quarterly earnings
Holding of earnings announcement : Yes

(Unit: Millions of Yen)

1. Results for the First Three Months of the Fiscal Year Ending March 31, 2025
(1) Operating results
(% changes as compared with the corresponding period of the previous fiscal year)
Net Sales Operating profit Profit before tax Profit
Three months
111,946 17.4% 16,743 26.1% 16,979 29.0% 10,984 28.3%
ended Jun. 30, 2024
Three months
95,351 10.8% 13,277 20.1% 13,160 2.4% 8,561 7.1%
ended Jun. 30, 2023

Profit
Total
attributable to Basic earnings Diluted earnings
comprehensive
owners of the per share (Yen) per share (Yen)
income
parent
Three months ended Jun. 30, 2024 11,031 28.0% 24,618 8.0% 17.69 17.69
Three months ended Jun. 30, 2023 8,621 7.4% 22,790 4.4% 13.73 13.72
Note: The Company conducted a three-for-one stock split on common stock with an effective date of April
1, 2024. Basic earnings per share and diluted earnings per share have been calculated as if the stock
split had taken place at the beginning of the previous consolidated fiscal year.

(2) Financial condition

Equity attributable Equity attributable
Total assets Total equity to owners of the to owners of the
parent parent to total assets
As of Jun. 30, 2024 626,249 448,784 447,979 71.5
As of Mar. 31, 2024 618,920 432,897 432,045 69.8
2. Dividend
Dividend per share
First quarter Second quarter Third quarter Year-end Annual
(Yen) (Yen) (Yen) (Yen) (Yen)
Year ended Mar. 31, 2024 ￣ 42.00 ￣ 42.00 84.00
Year ending Mar. 31, 2025 ￣
Year ending Mar. 31, 2025
15.00 15.00 30.00
(Forecast) ￣
Notes:
1. Revision of dividends forecast for this period: No
2. The Company conducted a three-for-one stock split on common stock with an effective date of April 1,
2024. However, actual dividend amounts prior to this stock split are shown for the fiscal years ended
March 31, 2024.

3. Financial Forecast for the Year Ending March 31, 2025

(% changes as compared with the corresponding period of the previous fiscal year)
Profit attributable to Basic earnings
Net Sales Operating profit Profit before tax
owners of the parent per share (Yen)
Six months
ending Sep. 237,000 11.4% 37,000 9.4% 34,900 4.8% 23,000 3.7% 36.89
30, 2024
Year ending
510,000 10.5% 87,000 11.0% 82,500 10.6% 55,000 10.8% 88.21
Mar. 31, 2025
Note: Revision of financial forecast for this period: No

4. Other Information
(1) Significant changes in scope of consolidation:
No
(2) Changes in accounting policies and accounting estimates
1) Changes in accounting policies required by IFRS: No
2) Other changes in accounting policies: No
3) Changes in accounting estimates: No
(3) Number of outstanding stock (common stock)
1) Number of outstanding stock at the end of each fiscal period (including treasury stock):
629,371,116 shares as of Jun. 30, 2024; 629,371,116 shares as of Mar. 31, 2024
2) Number of treasury stock at the end of each fiscal period:
5,873,240 shares as of Jun. 30, 2024; 5,872,332 shares as of Mar. 31, 2024
3) Average number of outstanding stock for each period (cumulative):
623,498,103 shares for the three months ended Jun. 30, 2024
627,800,607 shares for the three months ended Jun. 30, 2023
Notes:
1. The Company has introduced Stock-Granting Employee Stock Ownership Plan (ESOP) Trust.
Company shares held by the trust are included in treasury stock and are excluded from calculations
of the number of treasury stock at the end of the fiscal period and the average number of
outstanding stock for the period.
2. The Company conducted a three-for-one stock split on common stock with an effective date of April 1,
2024. The number of outstanding stock at the end of the fiscal period, the number of treasury stock
at the end of the fiscal period, and the average number of outstanding stock for the period are
calculated as if the stock split had taken place at the beginning of the previous consolidated fiscal
year.
* Review of the accompanying quarterly consolidated financial statements by a certified public
accountant or auditing firm: Yes (optional)

* Explanation regarding the appropriate use of financial forecast and other information
1. Basic earnings per share have been revised from the figures indicated in the consolidated financial
forecast announced on May 9, 2024, in accordance with changes in the number of shares of
outstanding stock and treasury stock. No other figures in the financial forecast have been revised.
2. The forecasts and future projections contained herein have been prepared on the basis of rational
decisions given the information available as of the date of announcement of this document. These
forecasts do not represent a commitment by the Company, and actual performance may differ
substantially from forecasts for a variety of reasons. Please refer to “3) Consolidated financial
forecast” within “1. Qualitative information on quarterly financial results” on page 5 of the
attachment to this document for cautionary statements concerning the conditions and performance
forecasts that serve as the basis for these forecasts.
3. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website
on Tuesday, August 6, 2024.
Content of Supplementary Materials

1. Qualitative information on quarterly financial results 2

1) Operating performance analysis 2
2) Financial conditions analysis 4
3) Consolidated financial forecast 5
4) Operating risks 5
5) Business and financial issues to be addressed 5
6) Important management contracts, etc. 5
2. Condensed quarterly consolidated financial statements and notes 6
1) Condensed quarterly consolidated statement of financial position 6
2) Condensed quarterly consolidated statement of income 8
3) Condensed quarterly consolidated statement of comprehensive income 9
4) Condensed quarterly consolidated statement of changes in equity 10
5) Condensed quarterly consolidated statement of cash flows 11
6) Notes to the condensed quarterly consolidated financial statements 12
1. Key considerations on the basis for the preparation of condensed quarterly consolidated 12
financial statements
2. Notes related to the going concern assumption 12
3. Segment information 12

- 1 -
1. Qualitative information on quarterly financial results
1) Operating performance analysis
Future-related information contained in the text below is based on the judgement as of the end of
the fiscal period under review.
In the first quarter of the fiscal year ending March 31, 2025, the outlook for the global economy is
being adversely affected by both short-term factors, such as high borrowing costs and the
withdrawal of fiscal support, and long-term factors, including Russia's invasion of Ukraine, weak
productivity growth, and worsening geoeconomic fragmentation. However, we expect growth to
continue at a pace similar to fiscal 2023, driven by aggressive government spending and household
consumption, as well as an expansion of supply capacity, mainly due to an increase in labor market
participation.
On the healthcare front, as global society ages we expect to see efforts to optimize social security
expenditures and decentralize healthcare functions. Against this backdrop, prevention and self-
medication will become increasingly important. At the same time, healthcare disparities and the
issue of accessibility to healthcare will continue to persist. Furthermore, we anticipate
advancements in technological innovation such as gene analysis, ultrahigh sensitive measurement,
and miniaturization, which will be applied to healthcare. Demand for personalized medicine will
grow, and we expect the practical application of new treatment methods such as regenerative and
cellular medicine and genomic medicine. Additionally, we predict the widespread adoption of
artificial intelligence (AI) and the acceleration of digital transformation (DX) in the healthcare
sector, including the implementation and expansion of robotic technologies. We anticipate further
growth opportunities as a result.
Against this backdrop, we began sales of our own brand of hemostasis testing solutions in the
United States and EU countries*1, based on a mutual OEM supply initiative with Siemens
Healthcare Diagnostics Inc. in April 2024. This distribution is based on a global OEM agreement
on hemostasis products concluded in February 2023. Moving forward, we will gradually expand the
implementation of sales through this initiative on a global scale. This will enable Sysmex to
provide even more effective solutions under our own brand by combining our strengths with the
world’s leading hemostasis product portfolios. Starting with the United States and EU countries,
which have been vital areas of expansion in our hemostasis field, Sysmex will progressively extend
this new initiative to other countries and regions.
Also, our subsidiary, Sysmex Astrego AB, was awarded one of the UK's biggest science prizes, the
“Longitude Prize on AMR,” for the development of the PA-100 AST System, a rapid antimicrobial
susceptibility testing system. The prize is designed to reward and support teams of innovators who
have undertaken the challenge of transforming the conventional clinical workflows for infectious
diseases, thereby making greatest contribution to tackling the global issue of antimicrobial
resistance (AMR)*2. Since the prize launched in November 2014, more than 250 teams from around
the world have applied, with Sysmex Astrego AB standing out as the sole recipient. The Longitude
Prize on AMR will serve as a catalyst for Sysmex to further accelerate its efforts in expanding the
global market and its application coverage of the PA-100 AST System, which is set to revolutionize
conventional clinical workflows for infectious diseases. Through this testing system, Sysmex will
continue its contribution to tackling the universal threat of AMR.
Finally, we launched the HISCL™ VEGF*3 Assay Kit for Research Use and HISCL™ PEDF*4
Assay Kit for Research Use, research reagents for measuring secreted proteins in cell culture media
in regenerative cellular medicine, in Japan, starting from June 20, 2024. A challenge in regenerative
cellular medicine is that the manufacturing cost is higher than that of common small-molecule
drugs. It has been reported that labor costs, including staff-hours, for quality-control testing account
for approximately 70% of the manufacturing cost of cellular drugs. In addition, since cultured cells
themselves are the raw material for cellular therapeutics, they must be non-destructively inspected
and monitored in quality control testing. Currently, however, such an inspection is performed
manually, and its automation is a challenge. In combination with the Automated Immunoassay
System HISCL™-5000/HISCL™-800, these assay kits can automatically measure secreted proteins,
which are indicators of the engraftment ability and functional expression of transplanted cells, in
- 2 -
 just 17 minutes. This can make a significant contribution to greater efficiency and standardization
of work in quality control testing of cellular medicine.
*1 EU countries: Countries including EU member states, Iceland, Liechtenstein, and Norway
*2 Antimicrobial resistance (AMR): This phenomenon occurs when living organisms develop a
resistance to a drug, whose efficacy is reduced or nullified as a result. Bacteria that have
developed microbial resistance are known as antimicrobial-resistant bacteria. If drug-
resistant bacteria proliferate, antimicrobials will become less effective, making it difficult to
treat infections that would otherwise be mild and reversible.
*3 VEGF (vascular endothelial growth factor): A group of glycoproteins involved in
vascularization (the formation of new blood vessels in areas with no blood vessels during
embryogenesis) and angiogenesis (the formation of blood vessels by branching and elongating
from existing vessels).
*4 PEDF (pigment epithelium derived factor): A multifunctional secreted protein with anti-
angiogenic, anti-tumorigenic, and neurotrophic functions.

Net sales by destination

Three months ended Three months ended
YoY
June 30, 2023 June 30, 2024
(Previous
Amount Percentage of Amount Percentage of
period = 100)
(Millions of yen) total (%) (Millions of yen) total (%)
Japan 13,036 13.7 13,717 12.3 105.2

Americas 27,021 28.3 31,638 28.3 117.1

EMEA 28,775 30.1 34,726 31.0 120.7

China 16,722 17.6 19,522 17.4 116.7

Asia Pacific 9,795 10.3 12,340 11.0 126.0

Overseas subtotal 82,315 86.3 98,228 87.7 119.3

Total 95,351 100.0 111,946 100.0 117.4

In Japan, sales increased 5.2% year on year, to ¥13,717 million. Changes in the market
environment pushed up demand, which boosted sales of instruments in the medical robotics
business. Also, sales of hematology instruments increased.
Overseas, sales of instruments, reagents and maintenance services increased in the hematology
field, as did sales of hemostasis and urinalysis reagents. These factors, plus ongoing yen
depreciation, caused overseas sales to rise 19.3% year on year, to ¥98,228 million. The overseas
sales ratio rose 1.4 percentage point, to 87.7%.
Selling, general and administrative (SG&A) expenses expanded 19.5%, to ¥36,016 million.
Behind this rise were stemming from a greater headcount and inflation-fueled rises in personnel
costs, as well as higher expenses. R&D expenses increased 3.1% year on year, to ¥7,356 million.
As a result, during the first quarter of the fiscal year ending March 31, 2025, Sysmex recorded
consolidated net sales of ¥111,946 million, up 17.4% year on year. Operating profit was up 26.1%, to
¥16,743 million; profit before tax increased 29.0%, to ¥16,979 million, and profit attributable to
owners of the parent rose by 28.0%, to ¥11,031 million.

Performance by segment
(1) Headquarters
Sales of hemostasis and life science reagents increased, as did instrument sales in the medical
robotics business. As a result, sales in this segment rose 10.3% year on year, to ¥19,759 million.
On the profit front, SG&A expenses rose, but higher sales and an improved cost of sales ratio
pushed up segment profit (operating profit) 70.5%, to ¥10,748 million.
- 3 -
 (2) Americas RHQ
Sales of hematology and urinalysis reagents increased in North America, as well as Central and
South America. In North America, sales of maintenance services in the hematology and
urinalysis fields also increased. As a result, overall sales in the Americas grew 17.0% year on
year, to ¥29,785 million.
Despite the higher sales, segment profit (operating profit) fell 27.9%, to ¥1,789 million, owing
to higher SG&A expenses.
(3) EMEA RHQ
The transition to direct sales in Saudi Arabia contributed to segment performance. Sales
increased for hematology, urinalysis and hemostasis reagents. Accordingly, sales were ¥33,837
million, up 19.3% year on year.
Although SG&A expenses rose, higher sales caused segment profit (operating profit) to soar
71.0%, to ¥3,475 million.
(4) China RHQ
Sales of hematology and urinalysis reagents increased. Consequently, sales rose 16.7%, to
¥19,477 million.
However, segment profit (operating profit) decreased by 19.3%, to ¥557 million, despite the
higher sales, owing to deterioration in the cost of sales ratio and an increase in SG&A expenses.
(5) Asia Pacific RHQ
Sales of hematology instruments, reagents, and maintenance services grew. This led to a 31.0%
increase in sales, to ¥9,086 million.
Segment profit (operating profit) surged 87.3%, to ¥1,668 million, due to higher sales and an
improved cost of sales ratio, although SG&A expenses grew.

2) Financial conditions analysis

(1) Financial conditions
As of June 30, 2024, total assets amounted to ¥626,249 million, up ¥7,328 million from March
31, 2024. As main factors, we saw increases of ¥9,212 million in inventories, ¥1,941 million in
property, plant and equipment, ¥2,069 million on intangible assets, and ¥1,963 in trade and other
receivables (non-current assets), while trade and other receivables (current assets) fell ¥10,463
million.
Meanwhile, total liabilities as of June 30, 2024 were ¥177,465 million, down ¥8,558 million
from March 31, 2024. Principal decreases included trade and other payables, which was down
¥5,980 million, and accrued bonuses, which fell ¥5,641 million.
Total equity came to ¥448,784 million, up ¥15,887 million from March 31, 2024. Among
principal reasons, other components of equity rose ¥13,634 million. Equity attributable to owners
of the parent to total assets amounted to 71.5% on June 30, 2024, up 1.7 percentage points from
69.8% on March 31, 2024.

(2) Cash flows

As of June 30, 2024, cash and cash equivalents amounted to ¥76,757 million, up ¥1,249 million
from March 31, 2024.
Cash flows from various activities during the first quarter are described in more detail below.
(Cash flows from operating activities)
Net cash provided by operating activities was ¥17,966 million, up ¥6,622 million from the first
three months of the previous fiscal year. As principal factors, profit before tax provided ¥16,979
million (¥3,819 million more than in the preceding year) and a decrease in trade receivables
provided ¥17,019 million (up ¥4,557 million), while an increase in inventories used ¥6,030 million
(up ¥1,242 million), and income taxes paid amounted to ¥10,321 million (down ¥2,114 million).
(Cash flows from investing activities)
Net cash used in investing activities was ¥11,132 million (up ¥839 million). Among major
factors, purchases of property, plant and equipment used ¥4,743 million (up ¥18 million), and
- 4 -
 purchases of intangible assets used ¥5,484 million (up ¥133 million).
(Cash flows from financing activities)
Net cash used in financing activities was ¥9,010 million (down ¥1,569 million). This was mainly
due to dividends paid of ¥8,728 million (down ¥59 million).

3) Consolidated financial forecast

The Company maintains its consolidated financial forecasts, as announced on May 9, 2024.
These forecasts are based on information available as of the date of this release. Actual results
may differ materially from these forecast due to unforeseen factors and future events.

4) Operating risks
In the first quarter under review, no new operating risk emerged, and there were no material
changes to the operating risks outlined in our financial report for the previous fiscal year.

5) Business and financial issues to be addressed

There are no significant changes to the descriptions of “Priority business and financial issues to
be addressed” in “Part I: Corporate Information, Section 2: Business Overview, 1. Management
Policy, Management Environment and Issues to be Addressed” in the financial report for the
previous fiscal year.

6) Important management contracts, etc.

No conclusions of important management contracts or decisions regarding them were made
during the first quarter under review.

- 5 -
2. Condensed quarterly consolidated financial statements and notes
1) Condensed quarterly consolidated statement of financial position
(Unit: Millions of yen)

As of As of
March 31, 2024 June 30, 2024

Assets
Current assets
Cash and cash equivalents 75,507 76,757
Trade and other receivables 157,067 146,604
Inventories 79,123 88,335
Other short-term financial assets 1,310 1,053
Income taxes receivable 934 1,084
Other current assets 29,515 28,484
Total current assets 343,459 342,319
Non-current assets
Property, plant and equipment 116,693 118,635
Goodwill 17,221 18,138
Intangible assets 86,786 88,856
Investments accounted for using the
472 441
equity method
Trade and other receivables 21,435 23,399
Other long-term financial assets 14,034 14,132
Asset for retirement benefits 458 483
Other non-current assets 4,339 4,522
Deferred tax assets 14,018 15,320
Total non-current assets 275,461 283,929
Total assets 618,920 626,249

－ 6 －
 (Unit: Millions of yen)

As of As of
March 31, 2024 June 30, 2024

Liabilities and equity

Liabilities
Current liabilities
Trade and other payables 33,602 27,622
Lease liabilities 8,659 9,333
Other current financial liabilities 1,028 1,501
Income taxes payable 12,476 8,675
Provisions 1,159 1,160
Contract liabilities 16,591 17,084
Accrued expenses 21,643 23,490
Accrued bonuses 12,611 6,969
Other current liabilities 10,311 10,008
Total current liabilities 118,084 105,847
Non-current liabilities
Long-term loans payable 28,600 30,608
Lease liabilities 18,080 18,180
Other non-current financial liabilities 76 71
Liability for retirement benefits 2,239 2,442
Provisions 674 705
Other non-current liabilities 10,350 11,396
Deferred tax liabilities 7,917 8,214
Total non-current liabilities 67,938 71,617
Total liabilities 186,023 177,465
Equity
Equity attributable to owners of the parent
Capital stock 14,729 14,729
Capital surplus 20,830 20,831
Retained earnings 365,985 368,288
Treasury stock (12,315) (12,318)
Other components of equity 42,814 56,449
Total equity attributable to owners of the parent 432,045 447,979
Non-controlling interests 851 804
Total equity 432,897 448,784
Total liabilities and equity 618,920 626,249

－ 7 －
2) Condensed quarterly consolidated statement of income
(Unit: Millions of yen)

Three months ended Three months ended

June 30, 2023 June 30, 2024

Net sales 95,351 111,946

Cost of sales 44,942 51,906
Gross profit 50,408 60,039
Selling, general and administrative expenses 30,148 36,016
Research and development expenses 7,131 7,356
Other operating income 300 234
Other operating expenses 151 157
Operating profit 13,277 16,743
Financial income 253 213
Financial expenses 404 590
Share of profit (loss) of associates accounted for
(821) (770)
using the equity method
Foreign exchange gain (loss) 856 1,384
Profit before tax 13,160 16,979
Income taxes expenses 4,598 5,995
Profit 8,561 10,984

Profit attributable to
Owners of the parent 8,621 11,031
Non-controlling interests (59) (47)
Profit 8,561 10,984

(Unit: Yen)
Earnings per share
Basic 13.73 17.69
Diluted 13.72 17.69

－ 8 －
3) Condensed quarterly consolidated statement of comprehensive income
(Unit: Millions of yen)

Three months ended Three months ended

June 30, 2023 June 30, 2024

Profit 8,561 10,984

Other comprehensive income
Items that will not be reclassified
subsequently to profit or loss
Net gain (loss) on financial assets
measured at fair value through other 272 (736)
comprehensive income
Total 272 (736)
Items that may be reclassified subsequently
to profit or loss
Exchange differences on translation of
13,952 14,353
foreign operations
Share of other comprehensive
income of investments accounted for using 4 17
the equity method
Total 13,956 14,370
Total other comprehensive income 14,229 13,634
Comprehensive income 22,790 24,618

Comprehensive income attributable to

Owners of the parent 22,850 24,665
Non-controlling interests (59) (47)
Comprehensive income 22,790 24,618

－ 9 －
 4) Condensed quarterly consolidated statement of changes in equity
Three months ended June 30, 2023
(Unit: Millions of yen)

Equity attributable to owners of the parent

Non-
Total
Capital Capital Retained Treasury
Other controlling
components Total equity
stock surplus earnings stock interests
of equity

As of April 1, 2023 14,282 20,580 334,192 (314) 18,925 387,665 690 388,356
Profit － － 8,621 － － 8,621 (59) 8,561
Other comprehensive
－ － － － 14,229 14,229 0 14,229
income
Comprehensive income － － 8,621 － 14,229 22,850 (59) 22,790
Exercise of warrants 222 127 － － － 349 － 349
Cash dividends － － (8,788) － － (8,788) － (8,788)
Purchase of treasury
－ － － (0) － (0) － (0)
stock
Disposal of treasury
－ － － － － － － －
stock
Total transactions with
222 127 (8,788) (0) － (8,439) － (8,439)
the owners
As of June 30, 2023 14,504 20,707 334,025 (315) 33,154 402,077 631 402,708

Three months ended June 30, 2024

(Unit: Millions of yen)

Equity attributable to owners of the parent

Non-
Total
Capital Capital Retained Treasury
Other controlling
components Total equity
stock surplus earnings stock interests
of equity

As of April 1, 2024 14,729 20,830 365,985 (12,315) 42,814 432,045 851 432,897
Profit － － 11,031 － － 11,031 (47) 10,984
Other comprehensive
－ － － － 13,634 13,634 － 13,634
income
Comprehensive income － － 11,031 － 13,634 24,665 (47) 24,618
Exercise of warrants － － － － － － － －
Cash dividends － － (8,728) － － (8,728) － (8,728)
Purchase of treasury
－ － － (2) － (2) － (2)
stock
Disposal of treasury
－ 0 － 0 － 0 － 0
stock
Total transactions with
－ 0 (8,728) (2) － (8,731) － (8,731)
the owners
As of June 30, 2024 14,729 20,831 368,288 (12,318) 56,449 447,979 804 448,784

－ 10 －
5) Condensed quarterly consolidated statement of cash flows
(Unit: Millions of yen)

Three months ended Three months ended

June 30, 2023 June 30, 2024

Cash flows from operating activities

Profit before tax 13,160 16,979
Depreciation and amortization 8,368 9,786
Share of loss (profit) of associates accounted for using
821 770
the equity method
Loss on retirement of non-current assets 22 31
Decrease (increase) in trade receivable 12,462 17,019
Decrease (increase) in advance payments (363) (94)
Decrease (increase) in inventories (4,787) (6,030)
Increase (decrease) in trade payable (2,459) (3,637)
Increase (decrease) in accounts payable–other (1,824) (1,767)
Increase (decrease) in contract liabilities (1,109) (524)
Increase (decrease) in accrued expenses 1,481 1,063
Decrease/increase in consumption taxes
4,074 1,551
receivable/payable
Increase (decrease) in accrued bonuses (6,067) (5,975)
Other－net 123 (646)
Subtotal 23,905 28,527
Interest and dividend received 133 166
Interest paid (259) (405)
Income taxes paid (12,435) (10,321)
Net cash provided by (used in) operating activities 11,343 17,966
Cash flows from investing activities
Purchases of property, plant and equipment (4,724) (4,743)
Purchases of intangible assets (5,350) (5,484)
Payments resulting in an increase in long-term
(111) (258)
prepaid expenses
Purchases of investments in equity instruments (69) (801)
Payments into time deposits (581) (620)
Proceeds from withdrawal of time deposits 560 741
Other－net (15) 34
Net cash provided by (used in) investing activities (10,293) (11,132)
Cash flows from financing activities
Proceeds from long-term loans payable － 2,300
Repayments of long-term loans payable － (125)
Exercise of warrants 349 －
Dividends paid (8,788) (8,728)
Repayments of lease liabilities (2,140) (2,453)
Other－net (0) (2)
Net cash provided by (used in) financing activities (10,579) (9,010)
Effects of exchange rate changes on cash and cash
2,980 3,426
equivalents
Net increase (decrease) in cash and cash equivalents (6,548) 1,249
Cash and cash equivalents at the beginning of the term 69,460 75,507
Cash and cash equivalents at the end of the term 62,911 76,757

－ 11 －
6) Notes to the condensed quarterly consolidated financial statements
1. Key considerations on the basis for the preparation of condensed quarterly consolidated
financial statements
The condensed quarterly consolidated financial statements have been prepared in accordance
with Article 5, Paragraph 2 of the Standards for Preparation of Quarterly Consolidated
Financial Statements, etc. of Tokyo Stock Exchange, Inc. (However, in accordance with Article
5, Paragraph 5 of the Standards for the Preparation of Quarterly Financial Statements, some
disclosures in International Accounting Standard No. 34 “Interim Financial Reporting” are
omitted.)
2. Notes related to the going concern assumption
Not applicable
3. Segment information
1) Overview of reportable segments
The Group’s reportable segments are the constituent business units of the Group for
which separate financial data are available and that are examined on a regular basis for
the purpose of enabling the Managing Board to allocate managerial resources and evaluate
results of operations.
The Group is primarily engaged in the manufacture and sale of diagnostic instruments
and reagents. These businesses are conducted in Japan by the Company, and in the
Americas, EMEA, China and the Asia Pacific by headquarters established in those regions.
These companies formulate overarching strategies tailored to regional characteristics and
conduct business activities accordingly. Headquarters and other domestic and overseas
subsidiaries are independent management units that handle production and sales for each
region.
To date, we have organized reportable segments geographically. However, from the first
quarter under review, the Company has integrated its performance management system to
focus on managing company-specific segments in the interest of making performance
management more efficient. We have revised the reportable segments based on this
management approach. The five managing company-specific segments are “Headquarters,”
“Americas RHQ,” “EMEA RHQ,” “China RHQ,” and “AP RHQ.”
The companies included in these reportable segments are outlined below.

Reportable
Companies included in the reportable segments
segments
Headquarters Sysmex Corporation, 13 other domestic subsidiaries, Sysmex Inostics Inc.
(United States), Oxford Gene Technology Inc. (United Kingdom), Sysmex
Partec GmbH (Germany), HYPHEN BioMed, SAS (France), Sysmex Astrego
AB (Sweden), Sysmex Korea Co., Ltd. (South Korea), nine other companies
Americas RHQ Sysmex America, Inc., seven other subsidiaries in the Americas
EMEA RHQ Sysmex Europe SE, 27 other subsidiaries in the EMEA region
China RHQ Sysmex Shanghai ltd., three other subsidiaries in China
AP RHQ Sysmex Asia Pacific Pte Ltd., 10 other subsidiaries in the Asia Pacific region

2) Segment profit and operating results

Profit and operating results from continuing operations by reportable segment of the
Group are as follows;
Intersegment sales are determined based on market prices or costs of goods
manufactured.
Accounting policies of reporting segments are consistent with the Group’s accounting
policies indicated in the consolidated financial statements for the previous fiscal year
Segment information for the previous first quarter is based on the revised reportable
segment categories.

－ 12 －
 Three months ended June 30, 2023
(Unit: Millions of yen)

Reportable segment
Adjustments Consolidated
Head- Americas EMEA China (Note 1) (Note 2)
AP RHQ Total
quarters RHQ RHQ RHQ
Sales
Sales to
external 17,908 25,457 28,360 16,689 6,935 95,351 － 95,351
customers
Intersegme
28,279 10 217 0 4 28,512 (28,512) －
nt sales
Total 46,188 25,467 28,578 16,689 6,940 123,864 (28,512) 95,351
Segment
6,304 2,481 2,032 690 890 12,399 877 13,277
profit (loss)
Financial
－ － － － － － － 253
income
Financial
－ － － － － － － 404
expenses
Share of
profit (loss) of
associates
－ － － － － － － (821)
accounted for
using the
equity method
Foreign
exchange gain － － － － － － － 856
(loss)
Profit before
－ － － － － － － 13,160
tax
Income taxes
－ － － － － － － 4,598
expenses
Profit － － － － － － － 8,561
Notes:
1. Segment profit (loss) adjustments of ¥877 million include ¥825 million for the unrealized gains on
inventories and ¥52 million for the unrealized gains on non-current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly
consolidated statement of income.

－ 13 －
 Three months ended June 30, 2024
(Unit: Millions of yen)

Reportable segment
Adjustments Consolidated
Head- Americas EMEA China (Note 1) (Note 2)
AP RHQ Total
quarters RHQ RHQ RHQ
Sales
Sales to
external 19,759 29,785 33,837 19,477 9,086 111,946 － 111,946
customers
Intersegme
33,036 5 151 176 10 33,380 (33,380) －
nt sales
Total 52,796 29,790 33,988 19,654 9,097 145,326 (33,380) 111,946
Segment
10,748 1,789 3,475 557 1,668 18,238 (1,495) 16,743
profit (loss)
Financial
－ － － － － － － 213
income
Financial
－ － － － － － － 590
expenses
Share of
profit (loss) of
associates
－ － － － － － － (770)
accounted for
using the
equity method
Foreign
exchange gain － － － － － － － 1,384
(loss)
Profit before
－ － － － － － － 16,979
tax
Income taxes
－ － － － － － － 5,995
expenses
Profit － － － － － － － 10,984
Notes:
1. Segment profit (loss) adjustments of negative ¥1,495 million include negative ¥1,435 million for
the unrealized gains on inventories and negative ¥59 million for the unrealized gains on non-
current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly
consolidated statement of income.

－ 14 －